Access Pharmaceuticals, Inc. (OTC BB: ACCP), an emerging biopharmaceutical company, is committed to the development and commercialization of propriety products for the treatment and supportive care of cancer patients. Access’ products currently include ProLindac(TM), the company’s lead oncology drug which is currently in Phase 2 clinical testing; and MuGard(TM), a viscous, mucoadhesive rinse for the management of patients with mucositis. For further information, visit the Company’s web site at www.accesspharma.com.
- 18 years ago
QualityStocks
Access Pharmaceuticals, Inc. (OTC BB: ACCP)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Positions Non-Lethal Innovation at the Center of Public Safety Reform
WRAP offerings illustrate a broader industry trend toward building connected ecosystems rather than standalone products.…
-
Brownfield Gold Projects Could Hold an Edge in Today’s Permitting Environment
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.…